RT Journal Article
T1 Advances in Genetics of Regeneration in Metabesity.
A1 Gauthier, Benoit R
A1 Bermudez-Silva, Francisco J
K1 Animal model
K1 Cell therapy
K1 Genes
K1 Genetic networks
K1 Inflammation
K1 Metabolic diseases
K1 Regeneration
K1 Regenerative medicine
K1 Transgenic
AB 'Metabesity' is a recent term comprising a wide range of diseases with underlying metabolic disarrangements at its root, and whose aetiology lies in complex relationships among genes and the obesogenic environment to which individuals are currently exposed in most countries. Of note, epigenetic changes are increasingly being reported to play an outstanding role in carrying deleterious information that, together with susceptibility genes, boost the development of metabesity in subsequent generations. In this context, it is noteworthy to mention that the transition from the pre-industrial era to the current high-technology society and global economy, even after suffering two world wars, has been very fast. By contrast, evolution-driven processes, such as biological ones, are slow. In fact, there is a general consensus that at the metabolic level, adipogenic processes and thrifty pathways prevail over those promoting energy expenditure in a way that currently leads to metabolic diseases by excessive energy storage. In such an imbalanced social-biological scenario, genes that were beneficial in the past have shifted to becoming detrimental, i.e., favouring metabesity, which is quickly growing to reach pandemic proportions.
PB MDPI
SN 2073-4425
YR 2019
FD 2019-05-20
LK http://hdl.handle.net/10668/14032
UL http://hdl.handle.net/10668/14032
LA en
NO Gauthier BR, Bermúdez-Silva FJ. Advances in Genetics of Regeneration in Metabesity. Genes (Basel). 2019 May 20;10(5):383
NO The authors are supported by the Consejería de Salud, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010 to B.R.G. and PI-0247-2016 to F.J.B.S.), the Consejería de Economía, Innovación y Ciencia (P10.CTS.6359 to B.R.G.), the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III co-funded by Fondos FEDER (PI10/00871 and PI13/00593 to B.R.G., PI13/00309 and PI17/01004 to F.J.B.S.), Vencer el Cancer (B.R.G), DiabetesCero (B.R.G.), F.J.B.S. is the recipient of a “Nicolás Monardes” research contract from Consejería de Salud Junta de Andalucía (C-0070-2012). CIBERDEM is an initiative of the Instituto de Salud Carlos III.
DS RISalud
RD Apr 17, 2025